El equipo del Dr. Byrne participa en los avances contra las enfermedades neuromusculares. El Dr. Barry Byrne (Universidad de Florida), uno de los mayores expertos mundiales sobre la enfermedad de Pompe, y colaborador habitual en los congresos de la AEEG, involucrado en el tratamiento de uno de los primeros pacientes en recibir la primera terapia disponible para la distrofia muscular de Duchenne.
“It is an honor to care for the first patient to receive a commercially available dose of this important new therapy” said Barry Byrne, M.D., Ph.D., a professor of molecular genetics at the UF College of Medicine and the director of the Powell Center for Rare Disease Research and Therapy. Byrne is also the treating physician for one of 12 patients in the original human study of Exondys 51, previously called Eteplirsen. That patient has been receiving weekly infusions at UF Health for over three years.
